The issue of best treatment for chronic hepatitis C virus (HCV) infection is in constant flux,
not only in Western countries but also in Asia. Currently, pegylated-interferon plus ribavirin is …

Abstract The Asian-Pacific Association for the Study of the Liver (APASL) convened an
international working party on the “APASL consensus statements and recommendation on …

The COVID-19 pandemic has spread rapidly worldwide. It is common to encounter patients
with COVID-19 with abnormal liver function, either in the form of hepatitis, cholestasis, or …

Background: The recommended treatment for patients infected with hepatitis C virus
genotype 2 (HCV2) is pegylated interferon (peginterferon) and ribavirin for 24 weeks. Aim …

BACKGROUND/AIMS: The long-term outcomes of interferon-alpha (IFN-α) therapy in
hepatitis B e antigen (HBeAg) seropositive patients remain controversial. This study was …

Background The long-term benefit for chronic hepatitis C (CHC) patients treated with
interferon (IFN)/ribavirin (RBV) combination therapy remains unclear. We aimed to evaluate …

Recommended treatment for hepatitis C virus genotype 1 (HCV‐1) patients is peginterferon
plus ribavirin for 48 weeks. We assessed whether treatment duration of 24 weeks is as …

Abstract The Asian Pacific Association for the Study of the Liver (APASL) convened an
international working party on the “APASL Consensus Statements and Management …

BACKGROUND & AIMS: Dual chronic infection with hepatitis C virus (HCV) and hepatitis B
virus (HBV) is common in areas endemic for either virus. Combination therapy with ribavirin …

Genome-wide association studies have linked single nucleotide polymorphisms (SNPs)
near the interleukin-28B gene to the hepatitis C virus genotype 1 (HCV-1) response to …